Real-time bioluminescent assay for inhibitors of RNA and DNA polymerases and other ATP-dependent enzymes

Analytical Biochemistry

Volumn 408, Issue 2, 2011, Pages 226-234

  Gregory, Kalvin J ^a   Sun, Ye ^a   Chen, Nelson G ^a   Golovlev, Valeri ^a  

^a Sci Tec Inc   (United States)

Author keywords

Bioluminescence; Fragment based drug discovery (FBDD); Polymerase assay; Real time; Viral polymerase inhibitors

Indexed keywords

BIOLUMINESCENCE; DNA; DRUG PRODUCTS; RNA;

BIOLUMINESCENT ASSAY; DRUG DISCOVERY; HIV-1 REVERSE TRANSCRIPTASE; INHIBITION CONSTANTS; INHIBITOR CONCENTRATION; MICHAELIS-MENTEN; REAL TIME; SUBSTRATE CONCENTRATIONS;

ENZYME INHIBITION;

ADENOSINE TRIPHOSPHATE; DEOXYADENOSINE TRIPHOSPHATE; DNA POLYMERASE; EFAVIRENZ; ENZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA POLYMERASE;

ARTICLE; BIOLUMINESCENCE; DNA TEMPLATE; ENZYME INHIBITION; MICHAELIS CONSTANT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78149413695     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.08.016     Document Type: Article

References (46)

1. Gallant J.E., Gerondelis P.Z., Wainberg M.A., Shulman N.S., Haubrich R.H., St.Clair M., Lanier E.R., Hellman N.S., Richman D.D. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir. Ther. 2003, 8:489-506.
2. Tomaras G.D., Greenberg M.L. Mechanisms for HIV-1 entry: current strategies to interfere with this step. Curr. Infect. Dis. Rep. 2001, 3:93-99.
3. Nielsen M.H., Pederson F.S., Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005, 2:10.
4. Wang M., Ng K.K.S., Cherney M.M., Chan L., Yannopoulos C.G., Bedard J., Morin N., Nguyen-Ba N., Alaoui-Ismali M.H., Bethell R.C., James M.N.G. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. J. Biol. Chem. 2003, 278:9489-9495.
5. Liaw Y.F., Sung J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351:1521-1531.
6. Shi S.T., Herlihy H.S., Graham J.P., Nonomiya J., Rahavendran S.V., Skor H., Irvine R., Binford S., Tatlock J., Li H., Gonzalez J., Linton A., Patick A.K., Lewis C. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2009, 53:2544-2552.
7. Carroll S.S., Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 2006, 6:17-29.
8. Koch U., Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect. Disord. Drug Targets 2006, 6:31-41.
9. Hammond J.L., Rosario M.C., Wagner F., Mazur D., Kantaridis C., Purohit V.S., Durham L.K., Jagannatha S., DeBruin M.F. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. Hepatology 2008, 48:LB11.
10. Walthen M.W. Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol. 2002, 12:167-178.
11. White L.K., Yoon J.J., Lee J.K., Sun A., Du Y., Fu H., Snyder J.P., Plemper R.P. Nonnucleoside inhibitors of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob. Agents Chemother. 2007, 51:2293-2303.
12. Zhang Z., Walker M., Xu W., Shim J.H., Girardet J., Hamatake R.K., Hong Z. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2006, 50:2772-2781.
13. Boyer P.L., Currens M.J., McMahon J.B., Boyd M.R., Hughes S.H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 1993, 67:2412-2420.
14. Zhan P., Liu X., Li Z., Pannecouque C., De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem. 2009, 16:3903-3917.
15. McCown M.F., Rajyaguru S., Kular S., Cammack N., Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 2009, 53:2129-2132.
16. Qiu P., Sanfiorenzo V., Curry S., Guo Z., Liu S., Skelton A., Xia E., Cullen C., Ralston R., Greene J., Tong X. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res. 2009, 37:e74.
17. Gish R.G. Hepatitis B treatment: current best practices, avoiding resistance. Cleve. Clin. J. Med. 2009, 76(Suppl. 3):S14-S19.
18. Abraham A.M., Kavitha S., Joseph P., George R., Pillay D., Malathi J., Jesudason M.V., Sridharan G. Aciclovir resistance among Indian strains of herpes simplex virus as determined using a dye uptake assay. Indian J. Med. Microbiol. 2007, 25:260-262.
19. Czartoski T., Liu C., Koelle D.M., Schmechel S., Kalus A., Wald A. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J. Clin. Microbiol. 2006, 44:1584-1586.
20. Carrigan D.R., Knox K.K. Identification of interferon-resistant subpopulations in several strains of measles virus: positive selection by growth of the virus in brain tissue. J. Virol. 1990, 64:1606-1615.
21. Carrigan D.R., Kabacoff C.M. Identification of a nonproductive, cell-associated form of measles virus by its resistance to inhibition by recombinant human interferon. J. Virol. 1987, 61:1919-1926.
22. Ukkonen P., Korpela J., Suni J., Hedman K. Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7:518-523.
23. Munshi V., Lu M., Felock P., Barnard R.J.O., Hazuda D.J., Miller M.D., Lai M.T. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. Anal. Biochem. 2008, 378:121-132.
24. Lopes D.O., Regi-da-Silva C.G., Machado-Silva A., Macedo A.M., Franco G.R., Hoffmann J.S., Cazaux C., Pena S.D.J., Teixeira S.M.R., Machado C.R. Analysis of DNA polymerase activity in vitro using non-radioactive primer extension assay in an automated DNA sequencer. Genet. Mol. Res. 2007, 6:250-255.
25. Lahser F.C., Malcom B.A.A. Continuous nonradioactive assay for RNA-dependent RNA polymerase activity. Anal. Biochem. 2004, 325:247-254.
26. Mestres J., Veenman G.H. Identification of " latent hits" in compound screening collections. J. Med. Chem. 2003, 46:3441-3444.
27. Gribbon P., Andreas S. High-throughput drug discovery: what can we expect from HTS?. Drug Discov. Today 2005, 10:17-22.
28. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41:856-864.
29. Oprea T.J., Davis A.M., Teague S.J., Leeson P.D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41:1308-1315.
30. Erlanson D.A., McDowell R.S., O'Brian T. Fragment-based drug discovery. J. Med. Chem. 2004, 47:3463-3482.
31. Carr R.A.E., Congreve M., Murray C.W., Rees D.C. Fragment-based lead discovery: leads by design. Drug Discov. Today 2005, 10:987-992.
32. Sun Y., Jacobson K.B., Golovlev V. A multienzyme bioluminescent time-resolved pyrophosphate assay. Anal. Biochem. 2007, 367:201-209.
33. Lee R.T., Denburg J.L., McElroy W.D. Substrate-binding properties of firefly luciferase: II. ATP-binding site. Arch. Biochem. Biophys. 1970, 141:38-52.
34. Airth R.L., Rhodes W.C., McElroy W.D. The function of coenzyme A in luminescence. Biochem. Biophys. Acta 1958, 27:519-532.
35. Steghens J.P., Min K.L., Bernengo J.C. Firefly luciferase has two nucleotide binding sites: effect of nucleoside monophosphate and CoA on the light-emission spectra. Biochem. J. 1998, 336:109-113.
36. Reardon J.E., Miller W.H. Human immunodeficiency virus reverse transcriptase substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido 3′-deoxythymidine 5′-triphosphate. J. Biol. Chem. 1990, 265:20302-20307.
37. Polesky A.H., Steitz T.A., Grindley N.D.F., Joyce C.M. Identification of residues critical for the polymerase activity of the Klenow fragment of DNA polymerase I from Escherichia coli. J. Biol. Chem. 1990, 265:14579-14591.
38. Huang Z., Szostak J.W. A simple method for 3′-labeling of RNA. Nucleic Acids Res. 1996, 24:4360-4361.
39. Majumdar C., Abbotts J., Broder S., Wilson S.H. Studies on the mechanism of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 1988, 263:15657-15665.
40. Huber H.E., McCoy J.M., Seehra J.S., Richardson C.C. Human immunodeficiency virus 1 reverse transcriptase template binding, processivity, strand displacement synthesis, and template switching. J. Biol. Chem. 1989, 264:4669-4678.
41. Gopalakrishna S., Gusti V., Nair S., Sahar S., Gaur R.K. Template-dependent incorporation of 8-N3AMP into RNA with bacteriophage T7 RNA polymerase. RNA 2004, 10:1820-1830.
42. Ricchetti M., Buc H. Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J. 1990, 9:1583-1593.
43. de Kloe G.E., Bailey D., Leurs R., de Esch I.J.P. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov. Today 2009, 14:630-646.
44. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Caroll S.S., Pettibone D.J., O'Brian J.A., Ball R.G., Balani S.K., Lin J.H., Chen I.W., Schleif W.A., Sardana V.V., Long W.J., Burnes V.W., Eminin E.A. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39:2602-2605.
45. Gregory K.J., Sun Y. Reduction of sample evaporation in small volume microplate luminescence assays. Anal. Biochem. 2009, 387:321-323.
46. Auld D.S., Zhang Y.Q., Southall N.T., Rai G., Landsman M., MacLure J., Langevin D., Thomas C.J., Austin C.P., Inglese J. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. J. Med. Chem. 2009, 52:1450-1458.